Publications

  1. Athreya AP, Vande Voort JL, Shekunov J, Rackley SJ, Leffler JM, McKean AJ, Romanowicz M, Kennard BD, Emslie GJ, Mayes T, Trivedi M, Wang L, Weinshilboum RM, Bobo WV, Croarkin PE. Evidence for machine learning guided early prediction of acute outcomes in the treatment of depressed children and adolescents with antidepressants. J Child Psychol Psychiatry. 2022 Nov; 63 (11):1347-1358 Epub 2022 Mar 15
    View PubMed
  2. Kumar R, Garzon J, Yuruk D, Hassett LC, Saliba M, Ozger C, Oztosun C, Ahern K, Athreya AP, Singh B, Croarkin PE, Vande Voort JL. Efficacy and safety of lamotrigine in pediatric mood disorders: A systematic review. Acta Psychiatr Scand. 2022 Sep 9 Epub 2022 Sept 09
    View PubMed
  3. Singh B, MahmoudianDehkordi S, Voort JLV, Han X, Port JD, Frye MA, Kaddurah-Daouk R, Mood Disorders Precision Medicine Consortium (MDPMC). Metabolomic signatures of intravenous racemic ketamine associated remission in treatment-resistant depression: A pilot hypothesis generating study. Psychiatry Res. 2022 Aug; 314:114655 Epub 2022 May 28
    View PubMed
  4. Singh B, Vande Voort JL, Frye MA, Kung S. Can ketamine be a safe option for treatment-resistant bipolar depression? Expert Opin Drug Saf 2022 Jun; 21 (6):717-720 Epub 2022 Feb 28
    View PubMed
  5. Zhang CY, Voort JLV, Yuruk D, Mills JA, Emslie GJ, Kennard BD, Mayes T, Trivedi M, Bobo WV, Strawn JR, Athreya AP, Croarkin PE. A Characterization of the Clinical Global Impression Scale Thresholds in the Treatment of Adolescent Depression Across Multiple Rating Scales. J Child Adolesc Psychopharmacol. 2022 Jun; 32 (5):278-287
    View PubMed
  6. Singh B, Kung S, Schak KM, Bobo WV, Frye MA, Vande Voort JL. Comparative Effectiveness of Intravenous Ketamine and Intranasal Esketamine in Real-World Setting Among Patients with Treatment Refractory Depression. CNS Spectr. 2022 Apr; 27 (2):232
    View PubMed
  7. Singh B, Port JD, Pazdernik V, Coombes BJ, Vande Voort JL, Frye MA. Racemic ketamine treatment attenuates anterior cingulate cortex GABA deficits among remitters in treatment-resistant depression: A pilot study. Psychiatry Res Neuroimaging 2022 Mar; 320:111432 Epub 2021 Dec 24
    View PubMed
  8. Nunez NA, Coombes BJ, Romo-Nava F, Bond DJ, Vande Voort J, Croarkin PE, Leibman N, Gardea Resendez M, Veldic M, Betcher H, Singh B, Colby C, Cuellar-Barboza A, Prieto M, Moore KM, Ozerdem A, McElroy SL, Frye MA, Biernacka JM. Clinical and Genetic Correlates of Bipolar Disorder With Childhood-Onset Attention Deficit Disorder. Front Psychiatry. 2022; 13:884217 Epub 2022 Apr 14
    View PubMed
  9. Vande Voort JL, Orth SS, Shekunov J, Romanowicz M, Geske JR, Ward JA, Leibman NI, Frye MA, Croarkin PE. A Randomized Controlled Trial of Combinatorial Pharmacogenetics Testing in Adolescent Depression. J Am Acad Child Adolesc Psychiatry. 2022 Jan; 61 (1):46-55 Epub 2021 June 05
    View PubMed
  10. Singh B, Port JD, Voort JLV, Coombes BJ, Geske JR, Lanza IR, Morgan RJ, Frye MA. A preliminary study of the association of increased anterior cingulate gamma-aminobutyric acid with remission of depression after ketamine administration. Psychiatry Res. 2021 Jul; 301:113953 Epub 2021 Apr 20
    View PubMed
  11. Shekunov J, Lewis CP, Vande Voort JL, Bostwick JM, Romanowicz M. Clinical Characteristics, Outcomes, Disposition, and Acute Care of Children and Adolescents Treated for Acetaminophen Toxicity. Psychiatr Serv. 2021 Jul 1; 72 (7):758-765 Epub 2021 Apr 23
    View PubMed
  12. Parikh SV, Lopez D, Vande Voort JL, Rico J, Achtyes E, Coryell W, Goddard A, Goes F, Greden JF, Singh B, Kaplin A, Frye MA, Maixner D, Watson B, Drake K, Tarnal V, Riva-Posse P, Bobo WV, Bio-K Study Team Team. Developing an IV Ketamine Clinic for Treatment-Resistant Depression: a Primer. Psychopharmacol Bull. 2021 Jun 1; 51 (3):109-124
    View PubMed
  13. Hu Y, Kung S, Ozerdem A, Vande Voort JL, Singh B, McDonald WM, Riva-Posse P, Frye MA. Hypomania associated with high dose ketamine treatment. Bipolar Disord. 2021 Jun; 23 (4):426-428 Epub 2021 Feb 24
    View PubMed
  14. Fatih P, Kucuker MU, Vande Voort JL, Doruk Camsari D, Farzan F, Croarkin PE. A Systematic Review of Long-Interval Intracortical Inhibition as a Biomarker in Neuropsychiatric Disorders. Front Psychiatry. 2021; 12:678088 Epub 2021 June 02
    View PubMed
  15. Nunez NA, Joseph B, Pahwa M, Seshadri A, Prokop LJ, Kung S, Schak KM, Vande Voort JL, Frye MA, Singh B. An Update on the Efficacy and Tolerability of Oral Ketamine for Major Depression: A Systematic Review and Meta-Analysis. Psychopharmacol Bull. 2020 Sep 14; 50 (4):137-163
    View PubMed
  16. Ballard ED, Farmer CA, Shovestul B, Vande Voort J, Machado-Vieira R, Park L, Merikangas KR, Zarate CA Jr. Symptom trajectories in the months before and after a suicide attempt in individuals with bipolar disorder: A STEP-BD study. Bipolar Disord. 2020 May; 22 (3):245-254 Epub 2019 Dec 09
    View PubMed
  17. Sonmez AI, Kucuker MU, Kolla BP, Lewis CP, Kolla BP, Doruk Camsari D, Vande Voort JL, Schak KM, Kung S, Croarkin PE. Improvement in hypersomnia with high frequency repetitive transcranial magnetic stimulation in depressed adolescents: Preliminary evidence from an open-label study. Prog Neuropsychopharmacol Biol Psychiatry. 2020 Mar 8; 97:109763 Epub 2019 Oct 18
    View PubMed
  18. Bieber ED, Vande Voort JL, Croarkin PE, VON Drehle CT, Simon SM, Hopp BN, Heil HM, Romanowicz M. Documentation Practices for Transgender Youth Admitted to an Inpatient Psychiatric Unit. J Psychiatr Pract. 2020 Mar; 26 (2):153-159
    View PubMed
  19. Nunez NA, Singh B, Romo-Nava F, Joseph B, Veldic M, Cuellar-Barboza A, Cabello Arreola A, Vande Voort JL, Croarkin P, Moore KM, Biernacka J, McElroy SL, Frye MA. Efficacy and tolerability of adjunctive modafinil/armodafinil in bipolar depression: A meta-analysis of randomized controlled trials. Bipolar Disord. 2020 Mar; 22 (2):109-120 Epub 2020 Jan 07
    View PubMed
  20. Shekunov J, Blacker CJ, Vande Voort JL, Tillema JM, Croarkin PE, Romanowicz M. Immune mediated pediatric encephalitis - need for comprehensive evaluation and consensus guidelines. BMC Neurol. 2020 Feb 3; 20 (1):44 Epub 2020 Feb 03
    View PubMed
  21. Bieber ED, Edelsohn GA, McGee ME, Shekunov J, Romanowicz M, Vande Voort JL, McKean AJS. The Role of Parental Capacity for Medical Decision-Making in Medical Ethics and the Care of Psychiatrically Ill Youth: Case Report. Front Psychiatry. 2020; 11:559263 Epub 2020 Oct 23
    View PubMed
  22. Singh B, Bobo WV, Rasmussen KG, Stoppel CJ, Rico JA Jr, Schak KM, Biernacka JM, Frye MA, Vande Voort JL. The Association Between Body Mass Index and Remission Rates in Patients With Treatment-Resistant Depression Who Received Intravenous Ketamine. J Clin Psychiatry 2019 Nov 12; 80 (6)
    View PubMed
  23. Betcher HK, Vande Voort JL, Croarkin PE, Gandhi KD, Shekunov J, Larrabee BR, Limbeck MG, Rummans TA, Romanowicz M. Effects of Parental Opioid Use: Outcomes of Children of Parents in Medication-Assisted Treatment Compared to Healthy Controls. Prim Care Companion CNS Disord. 2019 Aug 15; 21 (4)
    View PubMed
  24. Bieber ED, Bieber DA, Romanowicz M, Vande Voort JL, Kolla BP, McKean AJS. Recurrent Isolated Sleep Paralysis Following Bupropion Cessation: A Case Report. J Clin Psychopharmacol 2019 Jul-Aug; 39 (4):407-409
    View PubMed
  25. Sonmez AI, Camsari DD, Nandakumar AL, Voort JLV, Kung S, Lewis CP, Croarkin PE. Accelerated TMS for Depression: A systematic review and meta-analysis. Psychiatry Res. 2019 Mar; 273:770-781 Epub 2018 Dec 07
    View PubMed
  26. Romanowicz M, Schak KM, Vande Voort JL, Leung JG, Larrabee BR, Palmer BA. Prescribing Practices for Patients With Borderline Personality Disorder During Psychiatric Hospitalizations. J Pers Disord.. 2019.
    View PubMed
  27. Nandakumar AL, Vande Voort JL, Nakonezny PA, Orth SS, Romanowicz M, Sonmez AI, Ward JA, Rackley SJ, Huxsahl JE, Croarkin PE. Psychometric Properties of the Patient Health Questionnaire-9 Modified for Major Depressive Disorder in Adolescents. J Child Adolesc Psychopharmacol. 2019 Feb; 29 (1):34-40 Epub 2018 Nov 02
    View PubMed
  28. Veldic M, Ahmed AT, Blacker CJ, Geske JR, Biernacka JM, Borreggine KL, Moore KM, Prieto ML, Vande Voort JL, Croarkin PE, Hoberg AA, Kung S, Alarcon RD, Keeth N, Singh B, Bobo WV, Frye MA. Cytochrome P450 2C19 Poor Metabolizer Phenotype in Treatment Resistant Depression: Treatment and Diagnostic Implications. Front Pharmacol. 2019; 10:83 Epub 2019 Feb 19
    View PubMed
  29. Romanowicz M, Vande Voort JL, Shekunov J, Oesterle TS, Thusius NJ, Rummans TA, Croarkin PE, Karpyak VM, Lynch BA, Schak KM. The effects of parental opioid use on the parent-child relationship and children's developmental and behavioral outcomes: a systematic review of published reports. Child Adolesc Psychiatry Ment Health. 2019; 13:5 Epub 2019 Jan 12
    View PubMed
  30. Steinauer LM, Leung JG, Burkey BW, McGrane IR, Letts V, Goren JL, Hoeft DM, Mullen S, Maroney M, Schak KM, Vande Voort JL. A Retrospective Multicenter Evaluation of Clozapine Use in Pediatric Patients Admitted for Acute Psychiatric Hospitalization. J Child Adolesc Psychopharmacol. 2018 Nov; 28 (9):615-619 Epub 2018 Oct 24
    View PubMed
  31. Markota M, McKean AJ, Romanowicz M, Schak KM, Croarkin PE, Vande Voort JL. Rehospitalization to a child and adolescent psychiatry unit: Role of trauma and bullying. Gen Hosp Psychiatry. 2018 Nov - Dec; 55:10-14 Epub 2018 Aug 30
    View PubMed
  32. Croarkin PE, Nakonezny PA, Deng ZD, Romanowicz M, Voort JLV, Camsari DD, Schak KM, Port JD, Lewis CP. High-frequency repetitive TMS for suicidal ideation in adolescents with depression. J Affect Disord. 2018 Oct 15; 239:282-290 Epub 2018 July 18
    View PubMed
  33. Lewis CP, Nakonezny PA, Blacker CJ, Vande Voort JL, Port JD, Worrell GA, Jo HJ, Daskalakis ZJ, Croarkin PE. Cortical inhibitory markers of lifetime suicidal behavior in depressed adolescents. Neuropsychopharmacology. 2018 Aug; 43 (9):1822-1831 Epub 2018 Mar 14
    View PubMed
  34. Na PJ, Yaramala SR, Kim JA, Kim H, Goes FS, Zandi PP, Vande Voort JL, Sutor B, Croarkin P, Bobo WV. The PHQ-9 Item 9 based screening for suicide risk: a validation study of the Patient Health Questionnaire (PHQ)-9 Item 9 with the Columbia Suicide Severity Rating Scale (C-SSRS). J Affect Disord. 2018 May; 232:34-40 Epub 2018 Feb 17
    View PubMed
  35. Shafi RMA, Vande Voort JL, Croarkin PE, Romanowicz M. Parent-Child Interaction Therapy in a Case of Global Developmental Delay and Leukoencephalopathy. Front Psychiatry. 2018; 9:427 Epub 2018 Sept 10
    View PubMed
  36. Romanowicz M, McKean AJ, Vande Voort J. A case of a four-year-old child adopted at eight months with unusual mood patterns and significant polypharmacy. BMC Psychiatry. 2017 Sep 11; 17 (1):330 Epub 2017 Sept 11
    View PubMed
  37. Vande Voort JL, Ballard ED, Luckenbaugh DA, Bernert RA, Richards EM, Niciu MJ, Park LT, Machado-Vieira R, Duncan WC Jr, Zarate CA Jr. Antisuicidal Response Following Ketamine Infusion Is Associated With Decreased Nighttime Wakefulness in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2017 Sep/Oct; 78 (8):1068-1074
    View PubMed
  38. Gonzalez SD, Williams AJ, Blacker CJ, Vande Voort JL, Schak KM, Nemeroff CB, Widge AK, Tohen M. Putative biological predictors of treatment response in bipolar disorders Personalized Medicine in Psychiatry.2017;1:(2):39-58.
  39. Vande Voort JL, Morgan RJ, Kung S, Rasmussen KG, Rico J, Palmer BA, Schak KM, Tye SJ, Ritter MJ, Frye MA, Bobo WV. Continuation phase intravenous ketamine in adults with treatment-resistant depression. J Affect Disord. 2016 Dec; 206:300-304 Epub 2016 Sept 12
    View PubMed
  40. Bobo WV, Vande Voort JL, Croarkin PE, Leung JG, Tye SJ, Frye MA. KETAMINE FOR TREATMENT-RESISTANT UNIPOLAR AND BIPOLAR MAJOR DEPRESSION: CRITICAL REVIEW AND IMPLICATIONS FOR CLINICAL PRACTICE. Depress Anxiety. 2016 Aug; 33 (8):698-710 Epub 2016 Apr 06
    View PubMed
  41. Jameson ND, Sheppard BK, Lateef TM, Vande Voort JL, He JP, Merikangas KR. Medical Comorbidity of Attention-Deficit/Hyperactivity Disorder in US Adolescents. J Child Neurol. 2016 Jun 22;
    View PubMed
  42. Ballard ED, Vande Voort JL, Bernert RA, Luckenbaugh DA, Richards EM, Niciu MJ, Furey ML, Duncan WC Jr, Zarate CA Jr. Nocturnal Wakefulness Is Associated With Next-Day Suicidal Ideation in Major Depressive Disorder and Bipolar Disorder. J Clin Psychiatry. 2016 Jun; 77: (6)825-31.
    View PubMed
  43. Ballard ED, Vande Voort JL, Luckenbaugh DA, Machado-Vieira R, Tohen M, Zarate CA. Acute risk factors for suicide attempts and death: prospective findings from the STEP-BD study. Bipolar Disord. 2016 Jun; 18 (4):363-72 Epub 2016 May 27
    View PubMed
  44. Vande Voort JL, Singh A, Bernardi J, Wall CA, Swintak CC, Schak KM, Jensen PS. Treatments and Services Provided to Children Diagnosed with Bipolar Disorder. Child Psychiatry Hum Dev. 2016 Jun; 47 (3):494-502
    View PubMed
  45. McKean AJ, Vande Voort JL, Bostwick JM. Re: "Telepharmacotherapy for Child and Adolescent Psychiatric Patients" by Cain and Sharp (J Child Adolesc Psychopharm 2016;26:221-228). J Child Adolesc Psychopharmacol 2016 Apr; 26 (3):305 Epub 2016 Mar 30
    View PubMed
  46. Schak KM, Vande Voort JL, Johnson EK, Kung S, Leung JG, Rasmussen KG, Palmer BA, Frye MA. Potential Risks of Poorly Monitored Ketamine Use in Depression Treatment. Am J Psychiatry. 2016 Mar 1; 173 (3):215-8
    View PubMed
  47. Lewis CP, Nakonezny PA, Ameis SH, Vande Voort JL, Husain MM, Emslie GJ, Daskalakis ZJ, Croarkin PE. Cortical inhibitory and excitatory correlates of depression severity in children and adolescents. J Affect Disord. 2016 Jan 15; 190:566-575 Epub 2015 Oct 28
    View PubMed
  48. Lewis CP, Port JD, Frye MA, Vande Voort JL, Ameis SH, Husain MM, Daskalakis ZJ, Croarkin PE. An Exploratory Study of Spectroscopic Glutamatergic Correlates of Cortical Excitability in Depressed Adolescents. Front Neural Circuits. 2016; 10:98 Epub 2016 Nov 29
    View PubMed
  49. Ballard ED, Luckenbaugh DA, Richards EM, Walls TL, Brutsche NE, Ameli R, Niciu MJ, Vande Voort JL, Zarate CA Jr. Assessing measures of suicidal ideation in clinical trials with a rapid-acting antidepressant. J Psychiatr Res. 2015 Sep; 68:68-73.
    View PubMed
  50. Iadarola N, Niciu MJ, Richards EM, Vande Voort JL, Ballard ED, Lundin NB, Nugent A, Machado-Vieira R, Zarate CA Jr. Ketamine and other NMDA receptor antagonists in the treatment of depression: a perspective review. Ther Adv Chronic Dis. 2015 May; 6(3):97-114.
  51. Xu AJ, Niciu MJ, Lundin NB, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Lithium and Valproate Levels Do Not Correlate with Ketamine's Antidepressant Efficacy in Treatment-Resistant Bipolar Depression. Neural Plast. 2015; 2015:858251 Epub 2015 June 07
    View PubMed
  52. Ballard ED, Ionescu DF, Vande Voort JL, Niciu MJ, Richards EM, Luckenbaugh DA, Brutsche NE, Ameli R, Furey M, Zarate CA Jr. Improvement in suicidal ideation after ketamine infusion: relationship to reductions in depression and anxiety. J Psychiatr Res. 2014 Nov; 58:161-6.
  53. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey M, Zarate CA Jr. Riluzole likely lacks antidepressant efficacy in ketamine non-responders. J Psychiatr Res. 2014 Nov; 58:197-9.
  54. Ionescu DF, Luckenbaugh DA, Niciu MJ, Richards EM, Slonena EE, Vande Voort JL, Brutsche NE, Zarate CA Jr. Effect of baseline anxious depression on initial and sustained antidepressant response to ketamine. J Clin Psychiatry. 2014 Sep; 75(9):e932-8.
  55. Vande Voort JL, He JP, Jameson ND, Merikangas KR. Impact of the DSM-5 attention-deficit/hyperactivity disorder age-of-onset criterion in the US adolescent population. J Am Acad Child Adolesc Psychiatry. 2014 Jul; 53(7):736-44.
  56. Lundin NB, Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Brutsche NE, Machado-Vieira R, Zarate CA Jr. Baseline vitamin B12 and folate levels do not predict improvement in depression after a single infusion of ketamine. Pharmacopsychiatry. 2014 Jul; 47(4-5):141-142.
  57. Niciu MJ, Luckenbaugh DA, Ionescu DF, Richards EM, Vande Voort JL, Ballard ED, Brutsche NE, Furey ME, Zarate CA Jr. Ketamine's antidepressant efficacy is extended for at least four weeks in subjects with a family history of an alcohol use disorder. Int J Neuropsychopharmacol.2014 Oct 31;18:(1):
  58. Ballard ED, Ionescu DF, Vande Voort JL, Slonena EE, Franco-Chaves JA, Zarate CA Jr, Grillon C. Increased fear-potentiated startle in major depressive disorder patients with lifetime history of suicide attempt. J Affect Disord. 2014 Jun; 162:34-8.
  59. Coburn JA, Vande Voort JL, Lahr BD, Van Dyke CT, Kroning CM, Wu TT, Gandhi MJ, Murray JA. Human leukocyte antigen genetics and clinical features of self-treated patients on a gluten-free diet. J Clin Gastroenterol. 2013 Nov-Dec; 47 (10):828-33
    View PubMed
  60. Vande Voort JL, Swintak CC, Wall CA, Rasmussen KG Jr. Methohexital-induced seizures during electroconvulsive therapy. J ECT. 2013 Mar; 29 (1):e4-5
    View PubMed
  61. Vande Voort JL, Svecova J, Jacobson AB, Whiteside SP. A retrospective examination of the similarity between clinical practice and manualized treatment for childhood anxiety disorders. Cognitive and Behavioral Practice. 2010; 17(3):322-8.
  62. Sim LA, Homme JH, Lteif AN, Vande Voort JL, Schak KM, Ellingson J. Family functioning and maternal distress in adolescent girls with anorexia nervosa. Int J Eat Disord. 2009 Sep; 42(6):531-9.
    View PubMed
  63. Vande Voort JL, Murray JA, Lahr BD, Van Dyke CT, Kroning CM, Moore SB, Wu TT. Lymphocytic duodenosis and the spectrum of celiac disease. Am J Gastroenterol. 2009 Jan; 104 (1):142-8
    View PubMed
  64. Krych EH, Vande Voort JL. Medical students speak: a two-voice comment on learning professionalism in medicine. Clin Anat. 2006 Jul; 19(5):415-8.
    View PubMed